🔎 Trials Near Me

Início › Câncer de Pulmão de Não Pequenas Células › Alabama

Ensaios clínicos de Câncer de Pulmão de Não Pequenas Células em Alabama

36 estudos para Câncer de Pulmão de Não Pequenas Células estão buscando participantes em locais em Alabama.

Cidades em Alabama

Texto oficial do estudo (Inglês)

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  • Southern Cancer Center Pc, Daphne
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT07361510

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

  • Dothan Hematology & Oncology, Dothan
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT07189871

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  • Southern Cancer Center Pc, Daphne
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT07361497

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • Alabama Oncology, Birmingham
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT06881784

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  • Central Alabama Research ( Site 0108), Birmingham
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07190248

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  • Alabama Oncology, Shelby, Alabaster
  • Alabama Oncology, Bessemer, Bessemer
  • Alabama Oncology, St Vincent's Birmingham, Birmingham
  • e mais 9
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07144280

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • University of Alabama at Birmingham, Birmingham
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07154290

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

  • Clearview Cancer Institute (Crestwood), Huntsville
  • Clearview Cancer Institute, Huntsville
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07489066

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • Clearview Cancer Institute, Huntsville
  • Infirmary Cancer Care, Mobile
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06890598

Pan-tumor MRD Study

  • Alabama Oncology, Birmingham
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06605404

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  • University of Alabama at Birmingham, Birmingham
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT06618287

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology, Birmingham
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06712316

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

  • UAB Medicine - UAB Hospital, Birmingham
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07488676

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

  • Southern Cancer Center, P.C., Daphne
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07365319

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • University of Alabama at Birmingham, Birmingham
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT05059444

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  • The University of Alabama, Birmingham
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06303505

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

  • UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 10 de set. de 2026 · NCT06914128

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Clearview Cancer Institute, Huntsville
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT06119581

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  • O'Neal Comprehensive Cancer Center at UAB, Birmingham
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06343402

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

  • Uni of Alabama at Birmingham, Birmingham
RecrutandoFase 1
Idades de 18 a 100 · Todos os sexos · Atualizado em 29 de jul. de 2026 · NCT06562192

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

  • University of Alabama at Birmingham, Birmingham
  • University of Alabama at Birmingham, IDS Pharmacy, Birmingham
  • University of Alabama at Birmingham, Birmingham
  • e mais 1
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de jul. de 2026 · NCT05208762

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  • Central Alabama Research, Birmingham
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de jun. de 2026 · NCT06216301

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

  • University of Alabama at Birmingham, Birmingham
RecrutandoFase 2
Idades de 18 a 89 · Todos os sexos · Atualizado em 15 de jun. de 2026 · NCT06364917

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis, Daphne
  • Thomas Hospital, Fairhope
  • Mobile Infirmary Medical Center, Mobile
  • e mais 1
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 3 de jun. de 2026 · NCT05642572

MYLUNG Consortium Part 3: Observational Study

  • Southern Cancer Center, PC, Daphne
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 18 de mai. de 2026 · NCT05885698

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

  • University of Alabama at Birmingham, Birmingham
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 8 de mai. de 2026 · NCT05363280

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis, Daphne
  • Thomas Hospital, Fairhope
  • Mobile Infirmary Medical Center, Mobile
  • e mais 1
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis, Daphne
  • Thomas Hospital, Fairhope
  • Mobile Infirmary Medical Center, Mobile
  • e mais 1
RecrutandoFase 2
18 Minutes · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT06031688

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

  • University of Alabama at Birmingham, Birmingham
  • University of South Alabama, Mobile
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 30 de abr. de 2026 · NCT05297734

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

  • The University of Alabama at Birmingham Hospital, Birmingham
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 24 de abr. de 2026 · NCT06841055

GEMINI-NSCLC: NSCLC Biomarker Study

  • Alabama Oncology, Birmingham
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 5 de fev. de 2026 · NCT05236114

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Birmingham
  • Massive Bio SYNERGY-AI site, Mobile
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

  • XCancer Research Network/Dothan Hematology & Oncology, Dothan
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 24 de out. de 2025 · NCT06228326

Fonte: ClinicalTrials.gov, dados obtidos em 1 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.